Although adrenocorticotropic hormone is the most commonly used treatment for infantile spasms in the United States, the optimal regimen for this indication is not known. The purpose of this study was to elucidate the optimal adrenocorticotropic hormone treatment duration. We conducted a retrospective chart review of response to adrenocorticotropic hormone among all patients with infantile spasms managed at our institution from January 2009 to September 2013. Treatment response was defined as clinical remission for greater than or equal to 28 days starting at any point within the adrenocorticotropic hormone course and remission of hypsarrhythmia (or definite EEG improvement if hypsarrhythmia was absent at baseline). For responders, the diagnostic and post-treatment EEG tracings were reviewed. Electroclinical remission was achieved in 21 of 39 patients (54%) receiving adrenocorticotropic hormone, including 11/25 (44%) receiving a long course (typically 12 weeks) and 10/14 (71%) receiving a short course (typically four weeks). The mean time to clinical remission was 5.8 days (median: 5 days; range: 1-20 days). Only one patient responded beyond two weeks of treatment. This study provides Class IV evidence that among patients with infantile spasms, the response to adrenocorticotropic hormone is most often determined early in the treatment course. Given the importance of rapid remission, clinicians should consider adding or changing treatment if infantile spasms do not resolve within two weeks of adrenocorticotropic hormone initiation. Further study is needed to determine the optimal adrenocorticotropic hormone regimen for infantile spasms.
Children’s and Emory users, request article from Emily Lawson.
Riikonen R. Recent advances in the pharmacotherapy of infantile spasms. CNS Drugs. 2014 Apr;28(4):279-90.
“The optimal dosage and duration of ACTH therapy is still unknown, and low doses of ACTH are as effective as high doses. Shorter treatment lag probably improves long-term cognitive outcome. ACTH is superior to vigabatrin for cognitive outcome in cryptogenic groups. Different corticosteroids and AEDs can be given as second-line drugs when first-line drugs are ineffective or are contraindicated.”
Hancock EC, Osborne JP, Edwards SW. Treatment of infantile spasms. Cochrane
Database Syst Rev. 2013 Jun 5;6:CD001770.
“Implications for practice: Hormonal treatment (prednisolone (not prednisone), tetracosactide depot, and ACTH) resolves spasms faster than vigabatrin and in more infants, but it is not yet clear whether this will result in better long-term outcomes. Hormonal treatment might improve development in those with no proven underlying neurological disease, but the evidence is not robust. It is important to note that if prednisolone or vigabatrin is used, high dosage is recommended. The optimum dose of ACTH (or tetracosactide) is not yet known. Vigabatrin may be the treatment of choice in tuberous sclerosis. Other treatments cannot be recommended on the basis of the evidence reviewed. No evidence from the RCTs indicates that it is necessary to treat EEG features rather than spasms. A clear statement on the optimum treatment for infantile spasms requires further research. Until additional study results become available, other factors (in particular, underlying aetiology and adverse reactions) will influence parents and clinicians about individual treatment choices.”
More PubMed results on ACTH and infantile spasms.
Also, see: Infantile Spasms.